Roche scores a notable PhIII success with Tecentriq combo in bladder cancer, but is this another case of too little too late?
Two years after Roche’s PD-L1 drug Tecentriq failed a key test for frontline bladder cancer as a monotherapy, investigators are back with Phase III evidence that their checkpoint tied to chemo can do some good for patients.
Their IMvigor130 study came through on the co-primary endpoint for progression-free survival, but they’ll have to wait for the data to mature more before they make the call on overall survival.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
